Reboot Your Age Program Matches Users with Health Care Providers Through New Partnership with ReviveHealth – Yahoo Finance

Great Age Reboot, Inc. Partners with ReviveHealth to Help More People Easily Access Virtual Health Care
CLEVELAND and JACKSONVILLE, Fla., Nov. 14, 2022 /PRNewswire/ — Great Age Reboot, Inc., a leading digital health and longevity company, announced today its partnership with ReviveHealth, a virtual health care and medication service provider. The partnership matches Reboot Your Age users with primary care teams to monitor their longevity journey. The Reboot Your Age longevity program and app help users build healthy habits to live younger for longer. ReviveHealth nurse practitioners answer health-related questions, track biomarkers and lab reports, and manage a Rebooter’s progress while providing high-quality primary and mental health care.
“While the Reboot Your Age program is self-guided—with information, tips, and motivation from our founder, longevity pioneer Michael Roizen, M.D.—the most successful outcomes occur when a care team supports users on their journey,” said Corey Bridges, General Manager, Great Age Reboot, Inc. “Our partnership with ReviveHealth provides access to affordable and convenient health care providers who understand how the Reboot Your Age program functions. Further, those providers understand the success users can achieve by building daily habits involving diet, physical activity, sleep, stress management, and brain health. The ReviveHealth upgrade takes the Reboot experience to the next level, and we look forward to identifying other strategic partnerships that optimize the longevity experience for our users.”
How it works
To get started, consumers download the Reboot Your Age app from the Apple App Store or Google Play and enjoy a free 10-day trial. If a user chooses to subscribe to the Reboot Your Age program—monthly or yearly—they can easily upgrade their subscription to the ReviveHealth plan by visiting The ReviveHealth team walks Reboot users through the upgrade program and connects them with a ReviveHealth nurse practitioner.
“We are thrilled to partner with Great Age Reboot, Inc. to connect accessible health care providers to Reboot Your Age users anywhere in the country,” commented Jeff Bernhard, CEO, ReviveHealth. “Through our virtual primary care, mental health, and pharmacy benefits model, we deliver whole-person care for Reboot users as they focus on their preventive health. As users move through their Reboot journey, program subscribers will be able to meet virtually with a credentialed health care professional for well and sick visits.”
Reboot Your Age program
Reboot Your Age subscriptions cost $34.99 with a monthly subscription or $299.99 for an annual subscription, and anyone can get started with a free 10-day trial.
Reboot plus ReviveHealth upgrade
The Reboot upgrade to the ReviveHealth program costs an additional $26.95 per month and includes access to a ReviveHealth nurse practitioner as well as ReviveHealth’s full suite of virtual health care offerings, including discounted prescription medications for more than 425 generic medications, free home delivery, and pharmacy consultation.
To get started on the Reboot Your Age program upgrade with ReviveHealth, please visit To explore ReviveHealth’s offerings, please visit
About Great Age Reboot, Inc.
Great Age Reboot, Inc. informs people about the medical advancements that will allow them to live longer and inspires them to prepare physically and mentally for more years of life. The company was founded by Michael Roizen, M.D., Chief Wellness Officer Emeritus of the Wellness Institute at the Cleveland Clinic. Using extensive and rigorous scientific data, the company built the Reboot Platform, which powers Reboot Your Age, a longevity program and app to guide users on a personalized journey to reclaim their prime years. To learn more, please visit and follow @GreatAgeReboot on Instagram, Facebook, LinkedIn, and TikTok.
About ReviveHealth
ReviveHealth™ is an affordable health care subscription solution providing employees and consumers fully integrated everyday whole-person care, including primary and urgent care, mental health therapy, physical therapy, pharmacy benefits, and care solutions across all 50 states. Serving over 500,000 members, ReviveHealth™ offers customizable offerings for employers, plans sponsors, individuals, associations and affinity groups with plans starting at less than $1/day.
View original content to download multimedia:
SOURCE Great Age Reboot, Inc.
Infinity Pharmaceuticals Inc (NASDAQ: INFI) reported an update from its MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel in front-line metastatic triple-negative breast cancer (TNBC) patients. Sixty-two patients were enrolled and evaluable for safety, and 57 (were evaluable for efficacy, with a median duration of follow-up of 10.0 months. Encouraging one-year progression-free survival rates in MARIO-3 1L TNBC study regardless of PD-L1 status. 52% increase in one-ye
Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled.
As cannabis users get older and/or as weed consumption among seniors becomes more common (it has quadrupled in the past seven years!) a group of scientists honed in on this large demographic of pot-smoking baby boomers..and guess what? Their results suggest that the use of whole-plant cannabis does not have a negative impact on cognition. In fact, the opposite is true. The study, done at the University of Colorado Boulder, examined the effects of cannabis use in adults aged 60 to 88 with no hist
Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease.
The BQ.1 and BQ.1.1 omicron sublineages jointly accounted for more coronavirus cases in the U.S. in the week through Nov. 12 than the BA.5 omicron variant, according to data from the Centers for Disease Control and Prevention.
The U.S. government's Supplemental Nutrition Assistance Program is designed to help low-income Americans pay for food, but it might have an additional benefit: slowing memory decline among seniors….
"While the (trial) results are not what we hoped, we are proud to have delivered a high quality, clear and comprehensive Alzheimer's dataset to the field," Roche said.
Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.
As RSV cases rise, TODAY meteorologist Dylan Dreyer shares what it was like for her children to get sick. Her baby was wheezing, her toddler was breathing fast.
Swiss pharmaceutical company Roche said the drug failed to slow patients' clinical decline, in contrast to positive results from Biogen earlier this year.
The fight against Alzheimer's disease was dealt yet another setback on Monday. Two late-stage treatment studies conducted by Roche, which the…
Moderna Inc (NASDAQ: MRNA) said that data shows its omicron-tailored vaccines, mRNA-1273.214 and mRNA-1273.222, produced a higher antibody response against BA.4/5 subvariants than its original shot in vaccinated and boosted adults. Moderna, however, said that in an exploratory analysis of approximately 40 participants, both bivalent vaccines demonstrated robust neutralizing activity against BQ.1.1, despite an approximately 5-fold drop in titers compared to BA.4/BA.5. Related: Moderna Shares Deep
You might be aware of the fact that there are foods that can ruin your sleep. There are also foods that you should avoid when you're stressed. On the other hand, a new study has found that eating a "psychobiotic diet" may not only lower stress but may also help you get a better night's sleep.The October 2022 study that was published in Molecular Psychiatry involved 45 adults between the ages of 18 and 59 years old who normally consumed a diet that was low in fiber. While all participants met wit
The listeria outbreak has been traced to six states so far.
Geoffrey Seymour discovered blood in his stool just before his 41st birthday, which turned out to be stage four cancer
Ontario is facing a "triple threat" of viruses, COVID-19, influenza and respiratory syncytial virus (RSV), contributing to "extraordinary pressure" on the pediatric healthcare system.
The company develops technology for patients with liver and pancreatic cancers, which are uniquely difficult to treat.
The disappointing results come weeks after a similar treatment developed by two competitors delivered promising data, infusing fresh hope into a field that has been marked by a string of failures.
(Reuters) -Roche's Alzheimer's drug candidate could not be shown to slow dementia progression in two drug trials, leaving rivals Biogen and Eisai as leaders in a high-stakes race to launch a treatment for the memory-robbing disease. Roche said in a statement on Monday that twin studies known as Graduate 1 and 2 had not reached their main goal of showing that the drug gantenerumab could preserve abilities such as remembering, solving problems, orientation and personal care in patients suffering from early stages of Alzheimer's disease. Within each study, volunteers were randomly assigned to receive either the injectable antibody drug gantenerumab or a placebo.
Public health experts continue to warn about a trifecta of illnesses — RSV, flu and COVID — that are swirling in many parts of the country.


Leave a Comment

Your email address will not be published. Required fields are marked *